MC
FOLD

Moors & Cabot’s Amicus Therapeutics FOLD Stock Holding History

Moors & Cabot’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11,550
Closed -$142K – 681
2019
Q2 		$142K Hold
11,550
– – 0.02% 525
2019
Q1 		$160K Sell
11,550
-1,000
-8% -$12.2K 0.02% 496
2018
Q4 		$123K Sell
12,550
-4,000
-24% -$44K 0.02% 477
2018
Q3 		$198K Buy
+16,550
New +$231K 0.02% 541

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Moors & Cabot's FOLD Position: Q3 2019 in Review

Moors & Cabot sold out of Amicus Therapeutics (FOLD) in Q3 2019, closing a stake of 11,550 shares — an estimated $142K sold.

Moors & Cabot first reported a position in FOLD in Q3 2018 and held it in 4 quarters. The position peaked at $198K in Q3 2018. 204 funds tracked by Wall St. Rank hold FOLD as of Q3 2019.

  • Moors & Cabot reported no remaining Amicus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Moors & Cabot sold 11,550 Amicus Therapeutics shares in Q3 2019, an estimated $142K.
  • Moors & Cabot first reported a position in Amicus Therapeutics in Q3 2018 and held it in 4 quarters.
  • Moors & Cabot's Amicus Therapeutics position peaked at $198K in Q3 2018.
  • 204 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2019.

Based on Moors & Cabot's 13F filing for Q3 2019, filed 22 Oct 2019.